ClinicalTrials.gg
RecruitingNCT06043934Updated Sep 21, 2023

Neural Mobilization With Intermittent Cervical Traction on Grip Strength, Sleep Quality, and Quality of Life in Cervical Radiculopathy

An interventional study of Neural Mobilization with Intermittent Cervical Traction and Neural Mobilization in Cervical Radiculopathy, sponsored by University of Lahore. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
35 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Radiculopathy with a site in Pakistan — 20 open to participants now, 27 under way, none of them phase 3. Radiculopathy · Pakistan.

Planned enrollment
4th of 71
85 · median 44
Started
2023
with 16 others
No phase
71 of 72
20 open now
Primary completion
2023-12
later than 4 of 26 live
Registered
33rd of 72
by date
Lead sponsor
6 of 72
University of Lahore

Among the 72 studies in Radiculopathy with a site in Pakistan, this one is the 4th largest by planned enrollment of the 71 interventional ones that give a count, is one of 17 that started in 2023, is one of 71 with no phase, reaches primary completion later than 4 of the 26 other live ones, and was the 33rd registered.

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

20 of the 72 studies in Radiculopathy with a site in Pakistan are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 35 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Radiculopathy with a site in Pakistan, or all of them as a file.
02

Study summary

Cervical radiculopathy commonly called "pinched nerve," occurs when a nerve in the neck is compressed or irritated where it branches away from the spinal cord. This may cause pain that radiates into the shoulder and/or arm, as well as muscle weakness and numbness.

Read the detailed description

Cervical radiculopathy (CR) is a disorder of the peripheral nervous system that affects the normal function of the cervical nerve roots (CNRs). It is frequently linked to chronic pain and daily functional limitations. The goal of the neural tissue mobilization technique is to restore the nervous system's capacity to tolerate the normal compressive, tensile, and frictional forces that are associated with day-to-day activities and to examine the neural tension in nerves and mobilize the nerves that exhibit neural tension through passive and active movements using tensioning and gliding. Cervical traction reduces pressure within the vertebral disks and unloads the structures of the spine by stretching muscles and ligaments. They are clinically important techniques that are easily understood by patients.

03

Conditions studied

  • Cervical Radiculopathy

Keywords

  • Cervical Radiculopathy
  • Pain
  • Sleep Quality
  • Quality of Life
  • Grip Strength
  • Intermittent Cervical Traction
  • Neural Mobilization
04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of any gender
  2. Age between 35 and 55 years
  3. Experience of unilateral upper-extremity pain, numbness, or paranesthesia. This must include a history of neck pain associated with radicular pain below the occiput and on one side of the neck, along with a tingling sensation on the lateral aspect of the elbow joint.
  4. Positive results in at least three out of four tests Spurling's test, Distraction test, Upper Limb Neurodynamic Test 1, and ipsilateral cervical rotation of less than 60°, according to a clinical prediction rule.

Exclusion criteria

Exclusion Criteria:

  1. History of previous cervical or thoracic spine surgery
  2. Bilateral upper-extremity symptoms
  3. Signs or symptoms of upper motor neuron disease
  4. Medical "red flags" (e.g. tumor, fracture, rheumatoid arthritis, osteoporosis, prolonged use)
  1. Injections in cervical spine in the past 2 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Neural Mobilization with Intermittent Cervical Traction

    Patients in this experimental group will receive neural mobilization with intermittent cervical traction and routine physical therapy.

    Other: Neural Mobilization with Intermittent Cervical Traction

  • Active comparator
    Neural Mobilization

    Patients in this control group will receive neural mobilization and routine physical therapy.

    Other: Neural Mobilization

Interventions

  • OtherNeural Mobilization with Intermittent Cervical Traction

    This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).

  • OtherNeural Mobilization

    This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort. In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).

06

What researchers measure

Primary outcomes

  1. Pain Intensity

    Pain intensity is assessed using the Visual Analogue Scale (VAS), a unidimensional measure of pain intensity. The scale ranges from 0 (no pain) to 10 (worst possible pain), with the patient asked to rate their current level of pain.

    Time frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 2nd week and 4th week of treatment session.

  2. Status of Sleep Quality

    Sleep quality is evaluated using the Chronic Pain Sleep Inventory (CPSI), a self- administered, a multidimensional questionnaire that assesses sleep disturbances related to chronic pain. Patients report their sleep-related difficulties on a scale of 0 to 100, where 0 represents never having sleep disturbances and 100 represents always having sleep disturbances.

    Time frame: Sleep quality will be measured at baseline, and change in sleep quality status will be measured at 2nd week and 4th week of treatment session.

  3. Change in Quality of Life

    Quality of Life (QOL) is assessed using the SF-36 questionnaire, a standard, validated instrument for measuring health-related quality of life. The SF-36 covers eight health domains: physical function, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Its score ranges from 0 to 100 with 0 representing poor quality of life and 100 representing good quality of life.

    Time frame: Quality of life will be measured at baseline, and change in quality of life will be measured at 2nd week and 4th week of treatment session.

  4. Change in Grip Strength

    Grip strength is evaluated using an isometric dynamometer, a device designed to assess the maximum isometric strength of the hand and forearm muscles. Grip strength for males range from 40 to 64 kg and for females from 20 to 38 kg

    Time frame: Grip Strength will be measured at baseline, and change in grip strength will be measured at 2nd week and 4th week of treatment session.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: After publication of manuscript.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2023, 3 months after the start.

Of 205 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 3 months is below that.

Counting every sponsor, half of 217 studies reached it within 12 months; a quarter within 5 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Dec 30, 2023
CompletionEst.
Jan 15, 2024
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06043934
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 1, 2023
Primary completion
Dec 30, 2023 (estimated)
Completion
Jan 15, 2024 (estimated)
Last update
Sep 21, 2023

Study contacts

Rabia Yaseen, MS
Contact
rabiayaseen4059@gmail.com
+923104334546
Ayesha Jamil, M.Phil
Contact
ayeshabutt031@gmail.com
+923244481031
Umair Ahmad, PhD
study director · The University of Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion